Clovis Oncology (CLVS)’s CO-1686 Demonstrates Compelling Clinical Activity And Progression-Free Survival (PFS) In Updated Phase 1/2 Study Results In Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
6/2/2014 9:38:18 AM
CHICAGO--(BUSINESS WIRE)--Clovis Oncology (NASDAQ:CLVS) announced today updated findings from the Phase 1 and early Phase 2 portions of its ongoing Phase 1/2 clinical study of CO-1686, the Company’s novel, oral, targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M. These data are being presented today in an oral presentation by Dr. Lecia Sequist at the 2014 American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Help employers find you! Check out all the jobs and post your resume.
comments powered by